VHOSPITAL.CLINIC · Differential Diagnosis
Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer
Clinical comparison — shared symptoms, key differences, distinguishing diagnostic tests, treatment pathways, and when to seek urgent evaluation.
Condition Overview
Condition A
Benign Prostatic Hyperplasia (BPH)
BPH is non-malignant enlargement of the prostate gland causing lower urinary tract symptoms including weak stream, frequency, urgency, and nocturia. It is nearly universal in men over 80; alpha-blockers and 5-alpha reductase inhibitors are first-line treatments.
Condition B
Prostate Cancer
Prostate cancer is the most common cancer in men, growing in the prostate gland. Most cases are slow-growing, but aggressive forms can spread rapidly; PSA screening and biopsy are key diagnostic tools.
Shared Symptoms — Why They're Confused
Both conditions present with 1 overlapping symptom, making clinical differentiation essential.
Key Clinical Differences
Benign Prostatic Hyperplasia (BPH)
- Non-malignant enlargement causing obstructive LUTS
- Hesitancy, weak stream, nocturia, incomplete emptying
- Smooth enlarged prostate on DRE
- PSA mildly elevated proportional to gland size
Prostate Cancer
- Malignant transformation of prostatic epithelium
- Often asymptomatic early — detected on PSA screening
- Hard, irregular, asymmetric nodule on DRE
- PSA velocity elevated; Gleason score on biopsy
Distinguishing Diagnostic Tests
| Test | Benign Prostatic Hyperplasia (BPH) | Prostate Cancer |
|---|---|---|
| Digital rectal examination (DRE) | Smooth, symmetrically enlarged, non-tender prostate | Hard or nodular area, irregular, asymmetric — concerning for malignancy |
| PSA + PSA velocity | PSA proportional to gland size; PSA velocity <0.75 ng/ml/year | PSA disproportionately elevated or rapidly rising (>0.75/year) |
| MRI prostate + biopsy | Benign hyperplastic nodules in transition zone; no PI-RADS 4/5 lesion | PI-RADS 4 or 5 lesion in peripheral zone; Gleason ≥6 on systematic biopsy |
Treatment Approaches
Benign Prostatic Hyperplasia (BPH)
- •Alpha-1 blockers (tamsulosin) for symptom relief
- •5-alpha reductase inhibitors (finasteride) to shrink gland
- •Surgical: TURP for refractory obstruction
Prostate Cancer
- •Active surveillance for low-risk (PSA <10, Gleason 6)
- •Radical prostatectomy or radiotherapy for localised disease
- •Androgen deprivation therapy for metastatic disease
When Doctors Consider Each Diagnosis
🔵 Consider Benign Prostatic Hyperplasia (BPH) when:
- →Smooth prostate, LUTS, PSA proportional to size, no PI-RADS 4/5 lesion
🟢 Consider Prostate Cancer when:
- →Hard nodule on DRE, rapidly rising PSA, PI-RADS 4/5 on MRI, Gleason ≥6 on biopsy
Explore Each Condition in Detail
Related Clinical Pages
Benign Prostatic Hyperplasia (BPH)
Medical References
Content on this page is informed by evidence-based clinical sources including:
- World Health Organization (WHO)Global health guidance and disease classification
- National Health Service (NHS)UK clinical guidelines and patient information
- National Institute for Health and Care Excellence (NICE)Evidence-based clinical practice guidelines
- Centers for Disease Control and Prevention (CDC)US public health data and clinical recommendations
- PubMed – NCBIPeer-reviewed biomedical literature and clinical studies
- Cochrane LibrarySystematic reviews and meta-analyses in evidence-based medicine
Not sure which condition applies to you?
Describe your symptoms and get a structured clinical assessment — possible causes, red flags, and recommended next steps.
Start Free AI Analysis →